The TROPION-Lung01 Phase III trial has yielded positive data for datopotamab deruxtecan (Dato-DXd), an investigational TROP2-directed antibody drug conjugate (A 23 October 2023
Bristol Myers Squibb has announced the first presentation of results from the Phase III CheckMate -901 trial involving Opdivo (nivolumab) at the 2023 European S 23 October 2023
At the annual congress of the European Society for Medical Oncology (ESMO), Seagen and Astellas Pharma have presented detailed data from the Phase III EV-302 st 23 October 2023
Britain’s largest drugmaker, AstraZeneca, has reported positive results from a planned interim analysis of the MATTERHORN Phase III trial. 20 October 2023
No cancer conference would be complete without Merck & Co presenting a mountain of data on its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab). 20 October 2023
Californian antiviral specialist Gilead Sciences has presented new data today supporting Sunlenca (lenacapavir) as an important treatment option for adults with 20 October 2023
Nearly five months have passed since the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place, and cancer-focused drugmakers are ready 19 October 2023
US biotech major Gilead Sciences has presented new long-term real-world data on its flagship medication Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofov 19 October 2023
Sanofi has presented new data from its Phase III program for Tzield (teplizumab-mzwv) at the 49th Annual ISPAD Conference, in The Netherlands. 18 October 2023
Positive results from the Phase III SEQUENCE study show the benefit of AbbVie’s blockbuster biologic Skyrizi (risankizumab) in Crohn's disease. 16 October 2023
Belgian drugmaker UCB has announced the first analyses of pooled data from two Phase III bimekizumab studies (BE HEARD I and BE HEARD II) in moderate to severe 13 October 2023
At the European Academy of Dermatology and Venerology (EADV) congress in Berlin, AbbVie is presenting positive results from the Phase IIb NCT04927975 study. 12 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.